| 摘要: |
| 目的:系统评价英夫利昔单抗(IFX)治疗静脉注射丙种球蛋白(IVIG) 无反应型川崎病(KD) 的有效性及安全性。方法:
计算机检索PubMed、the Cochrane Library、Medline、中国知网、万方数据库和中国生物医学文献数据库,收集各数据库从建库至
2020 年6 月有关IFX 治疗IVIG 无反应型KD 的文献,对符合纳入标准的文献应用RevMan 5. 3 进行Meta 分析。结果:共纳入
5 篇文献,包括IFX 治疗组(81 例)和再次IVIG 治疗对照组(211 例)。Meta 分析结果显示,IVIG 无反应型KD 患儿在首次IVIG
治疗无反应后,IFX 治疗组退热率明显高于再次IVIG 治疗对照组,差异有统计学意义(RR=1. 38,95%CI 1. 20~1. 59,P<0. 01),
但在冠状动脉损害(CALs)发生率及不良事件发生率方面两组患儿比较差异均无统计学意义(P>0. 05)。结论:目前证据表明,
IVIG 无反应型KD 患儿在首次IVIG 治疗无反应后,应用IFX 治疗较再次应用IVIG 治疗能更有效地控制体温,但两者在CALs
发生率及不良事件发生率方面比较差异无统计学意义。 |
| 关键词: 川崎病 静脉注射丙种球蛋白 英夫利昔单抗 Meta 分析 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2023.01.011 |
|
| 基金项目: |
|
| Efficacy and Safety of Infliximab in the Treatment of Intravenous Immunoglobulin Resistant Kawasaki Disease: A Systematic Review and Meta-Analysis |
| Wang Sibao, Pan Silin, Luo Gang, Ji Zhixian |
| (Qingdao Women and Children’ s Hospital, Qingdao University, Shandong Qingdao 266034, China) |
| Abstract: |
| Objective: To review the efficacy and safety of infliximab (IFX) in the treatment of intravenous immunoglobulin (IVIG)
resistant Kawasaki disease ( KD). Methods: PubMed, the Cochrane Library, Medline, CNKI, Wanfang Database and Chinese
Biological Medical Literature Databases were searched by computer, and the articles about IFX in the treatment of IVIG-resistant KD
from the establishment of each database to June 2020 were collected. Meta-analysis was performed on the articles that met the inclusion
criteria using Review Manager 5. 3. Results: A total of 5 articles were included, which was divided into IFX treatment group (81 cases)
and re-IVIG treatment control group (211 cases). The results of Meta-analysis showed that the antipyretic rate in the IFX treatment
group was significantly higher than that in the control group after the first IVIG treatment (RR=1. 38, 95%CI 1. 20-1. 59, P<0. 01),
but there was no significant difference in the incidence of coronary artery lesions (CALs) and adverse events between the two groups
(P>0. 05). Conclusion: At present, the evidence shows that after the first IVIG treatment, IFX treatment can control body temperature
more effectively than IVIG treatment in children with IVIG resistant KD, but there is no significant difference in the incidence of CALs
and adverse events between the two groups. |
| Key words: Kawasaki disease intravenous immunoglobulin infliximab Meta-analysis |
